Skip to Content

Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma

Download PQI pdf

Last Updated: September 10, 2026

By: Chris Elder, PharmD, BCOP

About this PQI

The purpose of this PQI is to discuss clinical considerations surrounding tafasitamab-cxix (tafasitamab) treatment for patients with relapsed/refractory (R/R) follicular lymphoma (FL).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI